Does β-Blockade for Treatment of Refractory Ventricular Fibrillation or Pulseless Ventricular Tachycardia Improve Outcomes?

Ann Emerg Med. 2020 Jul;76(1):42-45. doi: 10.1016/j.annemergmed.2020.01.025. Epub 2020 Mar 16.

Authors

Drew A Long¹, Brit Long¹, Michael D April²

Affiliations

¹ Department of Emergency Medicine, San Antonio Uniformed Services Health Education Consortium, Fort Sam Houston, TX.
² 2(nd) Brigade Combat Team, 4(th) Infantry Division, Fort Carson, CO; Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD.

PMID: 32192760
DOI: 10.1016/j.annemergmed.2020.01.025

No abstract available

Publication types

Editorial
Review

MeSH terms

Adrenergic beta-Antagonists / therapeutic use*
Anti-Arrhythmia Agents / therapeutic use*
Cardiopulmonary Resuscitation
Observational Studies as Topic
Randomized Controlled Trials as Topic
Systematic Reviews as Topic
Tachycardia, Ventricular / drug therapy*
Tachycardia, Ventricular / physiopathology
Treatment Outcome
Ventricular Fibrillation / drug therapy*
Ventricular Fibrillation / physiopathology

Substances

Adrenergic beta-Antagonists
Anti-Arrhythmia Agents